H.C. Wainwright analyst Emily Bodnar initiated coverage of Gracell Biotechnologies with a Buy rating and $6 price target. Gracell is a cell therapy company developing autologous and allogeneic CAR-T therapies for hematologic malignancies and solid tumors with its proprietary technology platforms, Bodnar tells investors in a research note.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on GRCL: